Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Radiopharm Theranostics Pretax Margin % Related Terms
Radiopharm Theranostics Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RADX vs VRTX, REGN, MRNA: Pretax Margin % Comparison
For the Biotechnology subindustry, Radiopharm Theranostics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiopharm Theranostics (RADX) has a Pretax Margin % of -831.49% as of Jun. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Radiopharm Theranostics and its competitors. According to the industry distribution chart, Radiopharm Theranostics ranks #758 out of 948 companies in the Biotechnology industry, placing it in the top 80%.
Is Radiopharm Theranostics' Pretax Margin % too high?
Radiopharm Theranostics' current Pretax Margin % is -831.49%. Based on the distribution chart, Radiopharm Theranostics ranks #758 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Radiopharm Theranostics has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Radiopharm Theranostics' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #758 out of 948 companies for Pretax Margin %. This places Radiopharm Theranostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Pretax Margin % is -831.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Based on GuruFocus' analysis, Radiopharm Theranostics (RADX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.34, compared to a current price of $2.08 — trading 11.1% below its estimated fair value. The current Pretax Margin % is -831.49%. Radiopharm Theranostics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Radiopharm Theranostics (RADX), the current Pretax Margin % is -831.49% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Radiopharm Theranostics (RADX) Overvalued in 2026?
Based on GuruFocus' analysis, Radiopharm Theranostics stock appears to be undervalued.
The current stock price of $2.08 is trading 11.1% below its estimated GF Value™ of $2.34.
GuruFocus considers Radiopharm Theranostics to be Modestly Undervalued.
Key valuation signals for RADX:
Pretax Margin %: -831.49%
GF Value™: $2.34 vs. price of $2.08 (11.1% below fair value)
No single metric tells the full story. See the RADX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
33GF Score
Get the complete analysis for RADX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RADX has been successfully added to your 
